BACKGROUND: Deficiency of X-linked inhibitor of apoptosis (XIAP), caused by BIRC4 gene mutations, is the second known cause of X-linked lymphoproliferative disease (XLP), a rare primary immunodeficiency that often presents with life-threatening hemophagocytic lymphohistiocytosis (HLH). Rapid diagnosis of the known genetic causes of HLH, including XIAP deficiency, facilitates the initiation of life-saving treatment and preparation for allogeneic hematopoietic cell transplantation (HCT). Until now, a rapid screening test for XIAP deficiency has not been available. METHODS: To develop a flow cytometric screening test for XIAP deficiency, we first used lymphoblastic cell lines generated from controls and patients with BIRC4 mutations to identify two commercially available antibodies specific for native intracellular XIAP. Next, we used these antibodies to study control whole blood leukocyte XIAP expression. We then studied XIAP expression in leukocytes from patients with XLP due to BIRC4 mutations, maternal carriers, and patients following HCT. RESULTS: XIAP was expressed by the majority of all whole blood nucleated cells in normal controls. In contrast, XIAP was absent or decreased in all lymphocyte subsets, monocytes and granulocytes from four unrelated patients with XLP due to BIRC4 mutations. Bimodal distribution of XIAP expression was evident in two maternal carriers, with significant skewing toward cells expressing normal XIAP. Bimodal distribution was also observed in a patient following HCT. CONCLUSIONS: Flow cytometric analysis of intracellular XIAP provides a rapid screening test for XLP due to XIAP deficiency. It also allows carrier detection and can be used to monitor donor versus recipient reconstitution following HCT. (c) 2009 Clinical Cytometry Society.
BACKGROUND: Deficiency of X-linked inhibitor of apoptosis (XIAP), caused by BIRC4 gene mutations, is the second known cause of X-linked lymphoproliferative disease (XLP), a rare primary immunodeficiency that often presents with life-threatening hemophagocytic lymphohistiocytosis (HLH). Rapid diagnosis of the known genetic causes of HLH, including XIAP deficiency, facilitates the initiation of life-saving treatment and preparation for allogeneic hematopoietic cell transplantation (HCT). Until now, a rapid screening test for XIAP deficiency has not been available. METHODS: To develop a flow cytometric screening test for XIAP deficiency, we first used lymphoblastic cell lines generated from controls and patients with BIRC4 mutations to identify two commercially available antibodies specific for native intracellular XIAP. Next, we used these antibodies to study control whole blood leukocyte XIAP expression. We then studied XIAP expression in leukocytes from patients with XLP due to BIRC4 mutations, maternal carriers, and patients following HCT. RESULTS:XIAP was expressed by the majority of all whole blood nucleated cells in normal controls. In contrast, XIAP was absent or decreased in all lymphocyte subsets, monocytes and granulocytes from four unrelated patients with XLP due to BIRC4 mutations. Bimodal distribution of XIAP expression was evident in two maternal carriers, with significant skewing toward cells expressing normal XIAP. Bimodal distribution was also observed in a patient following HCT. CONCLUSIONS: Flow cytometric analysis of intracellular XIAP provides a rapid screening test for XLP due to XIAP deficiency. It also allows carrier detection and can be used to monitor donor versus recipient reconstitution following HCT. (c) 2009 Clinical Cytometry Society.
Authors: Kazuhiro Kogawa; Susan M Lee; Joyce Villanueva; Daniel Marmer; Janos Sumegi; Alexandra H Filipovich Journal: Blood Date: 2002-01-01 Impact factor: 22.113
Authors: C S Duckett; V E Nava; R W Gedrich; R J Clem; J L Van Dongen; M C Gilfillan; H Shiels; J M Hardwick; C B Thompson Journal: EMBO J Date: 1996-06-03 Impact factor: 11.598
Authors: A D Crockard; J M Thompson; N A Boyd; D J Haughton; D R McCluskey; C P Turner Journal: Int Arch Allergy Immunol Date: 1997-10 Impact factor: 2.749
Authors: Steven M Chirieleison; Rebecca A Marsh; Prathna Kumar; Joseph K Rathkey; George R Dubyak; Derek W Abbott Journal: J Biol Chem Date: 2017-04-12 Impact factor: 5.157
Authors: Rebecca A Marsh; Lisa Madden; Brenda J Kitchen; Rajen Mody; Brad McClimon; Michael B Jordan; Jack J Bleesing; Kejian Zhang; Alexandra H Filipovich Journal: Blood Date: 2010-05-20 Impact factor: 22.113
Authors: Julie M Rumble; Karolyn A Oetjen; Paul L Stein; Pamela L Schwartzberg; Bethany B Moore; Colin S Duckett Journal: Cell Immunol Date: 2009-06-13 Impact factor: 4.868
Authors: Rebecca A Marsh; Kanchan Rao; Prakash Satwani; Kai Lehmberg; Ingo Müller; Dandan Li; Mi-Ok Kim; Alain Fischer; Sylvain Latour; Petr Sedlacek; Vincent Barlogis; Kazuko Hamamoto; Hirokazu Kanegane; Sam Milanovich; David A Margolis; David Dimmock; James Casper; Dorothea N Douglas; Persis J Amrolia; Paul Veys; Ashish R Kumar; Michael B Jordan; Jack J Bleesing; Alexandra H Filipovich Journal: Blood Date: 2012-11-06 Impact factor: 22.113